Literature DB >> 1334354

Influence of a kinin antagonist on acute hypotensive responses induced by bradykinin and captopril in spontaneously hypertensive rats.

J N Sharma1, J M Stewart, S S Mohsin, M Katori, R Vavrek.   

Abstract

We have evaluated the effects of a B2 receptor antagonist (B5630) of kinins on BK and captopril-induced acute hypotensive responses in anaesthetized SHR. Intravenous treatment of BK (1.0 microgram) and captopril (0.3 mg/kg) caused significant (p < 0.05) fall in the SBP and DBP. Whereas BK caused greater fall in the SBP (p < 0.05), DBP (p < 0.01) and duration of hypotension (p < 0.05) when administered after captopril (Fig 1 and 2). All the hypotensive effects of BK and captopril were significantly antagonised (p < 0.05) in the presence of B5630 (2.0 mg/kg). Further, the duration of hypotensive responses of BK and captopril were blocked (p < 0.05) by B5630. The agonists and BK-antagonist did not cause significant (p > 0.05) alterations in HR during the entire investigation. These findings provide evidence to support the suggestion that B2 receptor might be involved in the regulation of the hypotensive actions of BK and captopril. Kinins should also have valuable functions in the antihypertensive property of captopril-like drugs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1334354

Source DB:  PubMed          Journal:  Agents Actions Suppl        ISSN: 0379-0363


  2 in total

1.  Analysis of erectile responses to bradykinin in the anesthetized rat.

Authors:  Justin A Edward; Edward A Pankey; Ryan C Jupiter; George F Lasker; Daniel Yoo; Vishwaradh G Reddy; Taylor C Peak; Insun Chong; Mark R Jones; Samuel V Feintech; Sarah H Lindsey; Philip J Kadowitz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-06-08       Impact factor: 4.733

2.  Bradykinin B2 receptor-dependent enhancement of enalapril-evoked hypotension in ethanol-fed female rats.

Authors:  Mahmoud M El-Mas; Abdel A Abdel-Rahman
Journal:  J Cardiovasc Pharmacol       Date:  2011-01       Impact factor: 3.105

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.